Clinical trials: Living Alone
Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma
Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies
The clinical study will assess the safety and tolerability of escalating intratumoral doses of mRNA-2752 in participants with relapsed/refractory solid tumor malignancies or lymphoma.
- Trial name
- NCT03739931
- Testing
- mRNA-2752, Durvalumab
- Where
- 24 sites in United States, Australia and 1 more
- Volunteers
- 134 people
- Sponsor
- ModernaTX, Inc.
Healthy Volunteer
A Safety And Pharmacokinetic Study of Setrobuvir Alone and In Combination With Ritonavir-Boosted Danoprevir in Subjects With Mild Hepatic Impairment Compared to Healthy Controls
This multi-center, fixed-sequence, open-label, multiple-dose, 2-period study will evaluate the safety, tolerability and pharmacokinetics of setrobuvir alone or in combination with ritonavir-boosted danoprevir in subjects with…
- Trial name
- NCT01714154
- Testing
- danoprevir, ritonavir, setrobuvir
- Where
- 3 sites in Hungary, Poland
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Generalized Anxiety Disorder
A Study To Assess Adverse Events and Change in Disease Activity With Oral Cariprazine When Added to Antidepressant Therapies (ADTs) Compared to Placebo in Adult Participants With Generalized Anxiety Disorder (GAD) Who Have Had an Inadequate Response to ADTs Alone
Generalized anxiety disorder (GAD) is usually treated with antidepressant therapy (ADT); however, sometimes ADTs alone are not enough to adequately treat GAD.
- Trial name
- CAR aGAD Ph 2 (NCT04965272)
- Testing
- Cariprazine 0.75 mg/day, Cariprazine 1.5 mg/day, Cariprazine 3.0 mg/day
- Where
- 36 sites in United States
- Sponsor
- AbbVie
High Blood Pressure
A Clinical Study With Aliskiren Alone or in Combination Therapy With Diuretic Hctz in Venezuelan Hypertensive Patients.
This is an open-label, not controlled, sequential, dose escalation study of 16 weeks' duration. The study is composed of two periods: a 0-2 week optional wash-out period depending on previous antihypertensive treatment(s)…
- Trial name
- ANDROMEDA (NCT01056731)
- Testing
- Aliskiren and HCTZ
- Where
- 7 sites in Venezuela
- Volunteers
- 253 people
- Sponsor
- Novartis
Healthy
Feasibility Study Into the Contraceptive Effect of Estetrol
This is an open study in 50 young, healthy, female volunteers. Women who want to participate and who are using hormonal contraception stop using their hormonal contraceptive and wait for their first spontaneous menstruation (i.e.
- Trial name
- NCT00563472
- Testing
- estetrol, estetrol and desogestrel, estetrol and progesterone
- Where
- Netherlands
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Pantarhei Bioscience
Advanced Solid Tumors
A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
The purpose of this study is to investigate the safety and efficacy of BMS-986482 alone and as combination therapy in participants with advanced solid tumors.
- Trial name
- NCT06697197
- Testing
- BMS-986482, Pumitamig
- Where
- 21 sites in United States, Belgium and 7 more
- Volunteers
- 286 people
- Sponsor
- Bristol-Myers Squibb
Dyslipidemia/Glucose Metabolism Disorder
Fenofibrate and Metformin Fixed Combination vs Metformin - FAME METFO
To demonstrate in patients with T2DM and dyslipidemia not appropriately controlled with a statin and receiving metformin, the superiority of a fixed combination of fenofibrate and metformin vs metformin alone on TG and…
- Trial name
- NCT00362323
- Testing
- fenofibrate (F) + metformin (M) hydrochloride fixed combination, Metformin
- Where
- 70 sites in Czechia, France and 5 more
- Volunteers
- 482 people
- Sponsor
- Solvay Pharmaceuticals
Cognition Disorders in Old Age
Study on the Effectiveness and Safety of Two Olive Extract- Based (Olea Europea L. Folium) Supplements, Alone or Combined With a Mullein Extract (Verbascum Thapsus L. Herba Cum Floribus), for the Maintenance of Cognitive Function.
The goal of this clinical trial is to learn if two food supplements based on olive leaf extract, alone or combined with mullein extract, help maintain cognitive function in older adults with mild cognitive impairment (MCI).
- Trial name
- NCT07586410
- Testing
- ACTIVE TREATMENT 1 - OLI-COGNITIVE FOOD SUPPLEMENT, ACTIVE TREATMENT 2 - OLI-VERB-COGNITIVE FOOD SUPPLEMENT
- Where
- Italy
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- ISTITUTO FARMOCHIMICO FITOTERAPICO: EPO SRL
Non-Small Cell Lung Cancer
A Study of IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy Alone
The purpose of this study is to assess the efficacy and safety of gefitinib in patients who have progressed on first line gefitinib, comparing continuing gefitinib in addition to cisplatin plus pemetrexed combination chemotherapy…
- Trial name
- IMPRESS (NCT01544179)
- Testing
- Gefitinib, Pemetrexed, Cisplatin
- Where
- 61 sites in China, France and 9 more
- Volunteers
- 265 people
- Sponsor
- AstraZeneca
Advanced Hepatocellular Carcinoma
A Study of TAC-101 in Combination With TACE Versus TACE Alone in Asian Patients With Advanced Hepatocellular Carcinoma
The purpose of this study is to evaluate the efficacy and safety of TAC-101 after Transcatheter Arterial Chemoembolization (TACE) in patients with advanced, unresectable hepatocellular carcinoma (HCC) who are being scheduled for…
- Trial name
- NCT00756782
- Testing
- TAC-101
- Sponsor
- Taiho Oncology, Inc.
Diabetes type1
A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recent-onset Diagnosed Type 1 Diabetes (T1D)
The purpose of this study is to assess the safety and tolerability of different doses of AG019 administered alone or in combination with teplizumab in participants with recent-onset type 1 diabetes (T1D).
- Trial name
- NCT03751007
- Testing
- AG019 - Low Dose, Teplizumab, AG019 - High Dose
- Where
- 18 sites in United States, Belgium
- Volunteers
- 45 people
- Sponsor
- Precigen Actobio T1D, LLC
Metastatic Breast Cancer
Comparative Real World Tumor Response in Pre-menopausal Metastatic Breast Cancer Patients Treated With Palbociclib + Aromatase Inhibitor or Aromatase Inhibitor Alone
This study aims to assess real-world tumor response in pre/perimenopausal HR+/HER2- metastatic breast cancer (MBC) patients initiating palbociclib + aromatase inhibitor (AI) or AI alone as first-line therapy during the period on…
- Trial name
- NCT05012644
- Testing
- Palbociclib + aromatase inhibitor, Aromatase inhibitor
- Where
- United States
- Volunteers
- 197 people
- Sponsor
- Pfizer
Type 2 Diabetes
Study to Assess the Efficacy and Safety of Liraglutide in the Treatment of Type 2 Diabetes
Liraglutide injection is a glucagon-like peptide-1 (GLP-1) analogue that activates the cyclic adenosine monophosphate (cAMP) and mitogen-activated protein kinase (MAPK) pathway by binding to the GLP-1 receptor (GLP-1R),thus,it…
- Trial name
- NCT04373967
- Testing
- Victoza®., Metformin Hydrochloride, TQZ2451
- Where
- 46 sites in China
- Volunteers
- 424 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Type 2 Diabetes
Evaluation of Dapagliflozin Taken Twice-daily
This study is being carried out to see if dapagliflozin - administered in a daily dose of 2.5 mg given twice a day or 5 mg twice a day or 10mg once daily - in addition to metformin, is beneficial in diabetes treatment, and if so…
- Trial name
- NCT01217892
- Testing
- dapagliflozin, metformin
- Where
- 55 sites in Germany, Hungary and 5 more
- Volunteers
- 400 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Efficacy and Safety of Lobeglitazone Versus Sitagliptin
Efficacy and Safety of Lobeglitazone versus Sitagliptin in inadequately controlled by Metformin alone Type 2 Diabetes mellitus Patients with Metabolic syndrome.
- Trial name
- NCT02480465
- Testing
- Lobelitazone 0.5mg, Sitagliptin 100mg
- Where
- South Korea
- Volunteers
- 248 people
- Sponsor
- Chong Kun Dang Pharmaceutical
HIV Infections
A Pharmacokinetic Study of L-697,661 Alone and in Combination With Zidovudine
Part 1: To study the potential safety and pharmacokinetic (blood level) effects of zidovudine (AZT) on L-697,661; to obtain additional pharmacokinetic information in humans with L-697,661; to study the effect of L-697,661 on…
- Trial name
- NCT00000628
- Testing
- L-697,661, Zidovudine
- Where
- 5 sites in United States
- Volunteers
- 27 people
- Sponsor
- Merck Sharp & Dohme LLC
Urothelial Cancer
A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)
The main purpose of this study is to compare maintenance treatment with avelumab plus best supportive care (BSC) with BSC alone, to determine if avelumab has an effect on survival in patients with locally advanced or metastatic…
- Trial name
- NCT02603432
- Testing
- Avelumab, Best Supportive Care, Following the planned interim analysis for this study: Avelumab
- Where
- 382 sites in United States, Argentina and 27 more
- Volunteers
- 700 people
- Sponsor
- Pfizer
Breast Cancer
Study Evaluating Bosutinib-Letrozole Combination Versus Letrozole Alone In Post Menopausal Women With Breast Cancer
This is a phase 2 study of bosutinib administered in combination with letrozole versus letrozole alone in post-menopausal women with breast cancer. This is a 2-part study.
- Trial name
- NCT00880009
- Testing
- Bosutinib, Letrozole
- Where
- 11 sites in United States, Belgium and 5 more
- Volunteers
- 16 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy
The primary objective of this study is to evaluate the effects of filgotinib in combination with methotrexate (MTX) versus MTX alone in adults with active rheumatoid arthritis (RA).
- Trial name
- FINCH 3 (NCT02886728)
- Testing
- Filgotinib, MTX
- Where
- 186 sites in United States, Argentina and 29 more
- Volunteers
- 1,252 people
- Sponsor
- Gilead Sciences
Diabetic Foot Ulcers
A Comparison of the dermaPACE® (Pulsed Acoustic Cellular Expression) Device in Conjunction With Standard of Care Versus Standard of Care Alone in the Treatment of Diabetic Foot Ulcers
The Sponsor of this study, SANUWAVE, Inc., has developed an investigational device known as the dermaPACE® (Pulsed Acoustic Cellular Expression) device for the possible treatment of diabetic foot ulcers.
- Trial name
- NCT01824407
- Testing
- Electrohydraulic-generated shock wave
- Where
- 19 sites in United States, Canada
- Volunteers
- 90 people
- Sponsor
- SANUWAVE, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.